RCS - Kromek Group PLC - Capital Markets Day Presentation

KromekAnnouncement

Mon 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nRSW9939Na&default-theme=true

RNS Number : 9939N  Kromek Group PLC  23 June 2025

23 June 2025

 

Kromek Group plc

("Kromek" or the "Group")

 

Capital Markets Day Presentation

 

Kromek (AIM: KMK), a global detection company delivering best-in-class
solutions for the advanced imaging and CBRN detection markets, is pleased to
announce that a recording of the presentation delivered at its capital markets
day held on 18 June 2025 is available on the Group's website at:
https://www.kromek.com/cmd-25/ (https://www.kromek.com/cmd-25/) .

 

The recording is also available on the Investor Meet Company platform where
the Group will be hosting an online Q&A session for retail investors
at 5.00pm on Wednesday 25 June 2025. Investors can sign up to Investor Meet
Company for free and register to attend the Kromek Q&A session via:

https://www.investormeetcompany.com/kromek-group-plc/register-investor
(https://www.investormeetcompany.com/kromek-group-plc/register-investor) .

 

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Tim Redfern - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

 In CBRN detection, the Group provides nuclear radiation detection solutions
to the global homeland defence and security market. Kromek's compact,
handheld, high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily used to
protect critical infrastructure, events, personnel and urban environments from
the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUMWQUPAGUW